About Medimaps
We understand bone health
Founded by clinicians and researchers, Medimaps unites Swiss scientific rigour and Nordic AI engineering to lead the assessment of bone quality worldwide.
Our makeup
Who is Medimaps?
Founded by medical practitioners and clinical researchers, Medimaps combines Swiss innovation with a global presence to lead in bone-health management. We give healthcare professionals worldwide advanced AI-driven software for comprehensive bone-microarchitecture assessment — and, since our 2026 merger with Radiobotics, for automated fracture detection from everyday X-rays.
Our passion for musculoskeletal health is grounded in science and in collaboration with world-class academics, clinicians, and industry partners. The science behind our imaging applications, and the clinical evidence beneath it, is the core of who we are.
Our value
What does Medimaps do?
As pioneers in bone-microarchitecture assessment, we build medical imaging AI that helps clinicians see bone quality — not just bone density — and act on it earlier. Our software transforms bone-health management and supports better treatment decisions across the patient pathway.
We aim to be present at every stage of bone health, from opportunistic screening, to diagnosing bone health or fractures, to surgical planning.
We also partner with pharmaceutical and medical-device companies, providing professional services in the development of novel osteoporosis and orthopaedic treatments.
Our vision
Creating an era where healthy bones are the norm
Our mission is to help clinicians reveal more from routine imaging — every patient, every scan — for better care
Our story
Nearly two decades of bone science
2012
Medimaps is founded
Medimaps is founded to develop and commercialise the science of bone microarchitecture — the creators of TBS®
2019
Central CRO service launches
Medimaps establishes its centralised CRO analysis service, bringing TBS® to pharmaceutical trials worldwide
2022
US reimbursement begins
The first reimbursable TBS® CPT® codes take effect in the United States
March 2026
Medimaps and Radiobotics merge
Medimaps and Radiobotics merge, bringing together the world's leading bone-microarchitecture technology and one of Europe's most widely deployed AI fracture-detection tools
June 2026
TBS Reveal receives CE MDR certification
Opportunistic bone-fragility assessment from routine X-rays becomes available for clinical use across Europe
June 2026
80+ people, three offices, 90+ countries
A portfolio spanning DXA and X-ray, built by a team across Switzerland, Denmark, and the US
Medimaps · 2026
Two leaders in bone imaging, now one company
In early 2026, Medimaps and Radiobotics merged, bringing together the world's leading bone-microarchitecture technology and one of Europe's most widely deployed AI fracture-detection tools.
+
80+
employees across three continents
3
offices: Geneva, Copenhagen, and Wilmington
2
clinical modalities: DXA and X-ray
90+
countries with clinical deployments7
Culture and benefits
The people behind the science
Our people are our driving force. It takes a whole team to build tomorrow's solutions, and at Medimaps everyone plays a real part, regardless of age, gender, or background.
We're passionate, ambitious, and science-led, but it's the day-to-day culture that sets us apart: Colleagues who have lunch together, do yoga together, and mark milestones and birthdays as a team, no matter where they are located around the world.
- Home-office flexibility
- Competitive salary
- Professional training
- Office-specific benefits, e.g. showering, sports facilities, and subsidized parking
Credibility
Certified to the standard of field experts
ISO 13485:2016
Certified by DNV (certificate C831121)
MDSAP
One audit, recognised by FDA, Health Canada, TGA, ANVISA, and PMDA
EU MDR
Our products meet Regulation (EU) 2017/745 for EU safety and quality
We're looking forward to meeting you.